Needham Maintains AtriCure as Top Small/Mid-Cap Pick; Warns on Lower Revenue for Q4 Following Management Preannouncement However Highlights Upcoming Data from aMAZE Trial within Late 2021 as Major Catalyst with Near-Term Growth Driven by New Products